Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials

Lopez, Anthony; Ford, Alexander C; Colombel, Jean–Frédéric; Reinisch, Walter; Sandborn, William J.; Peyrin–Biroulet, Laurent

doi:10.1016/j.dld.2015.01.148

Cited by 37 publications

(42 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with moderate-to-severe active UC treated with IFX at weeks 0, 2, and 6 and every 8 weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo. Meta-analyses confirmed that IFX is more effective than placebo to induce and maintain clinical remission and mucosal healing in UC [14,15]. IFX is associated with less hospitalisations and reduces the need for colectomy.…”

Section: Ifx and Calcineurin Inhibitors For Ucmentioning

confidence: 72%

Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis

Takeuchi

Shimoyama

Yamamoto³

2017

Dig Dis

View full text Add to dashboard Cite

Background: This narrative review was to determine which medication, tacrolimus (TAC) or infliximab (IFX), is safer and more effective in the management of active UC. Our literature search identified 5 studies directly comparing the outcomes of TAC versus IFX for active UC. A review of the 5 studies was undertaken. Summary: The incidence of serious adverse events was not significantly different between the TAC and IFX groups. The short-term clinical remission and response rates and the colectomy-free rates were similar between the groups. TAC was usually withdrawn at week 12 and, therefore, the long-term efficacy of TAC could not be properly evaluated. The majority of patients in the IFX group maintained clinical remission in the long-term. The efficacy of IFX as second-line salvage therapy after failure of TAC appeared to be favourable, but the efficacy of TAC after failure of IFX was questionable. Key Messages: Both TAC and IFX appeared to be equally safe and effective in the short-term for patients with active UC. For the moment, treatment choice, TAC or IFX, should be guided by physician and centre experience. Randomised controlled trials are urgently warranted to rigorously compare the efficacy of TAC versus IFX for active UC.

show abstract

Section: Ifx and Calcineurin Inhibitors For Ucmentioning

confidence: 72%

Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis

Takeuchi

Shimoyama

Yamamoto³

2017

Dig Dis

View full text Add to dashboard Cite

show abstract

“…13 Yet anti-TNF therapy, most often intravenous infliximab or subcutaneous adalimumab, is generally resorted to whenever these initial treatments do not achieve their goal. 21 Indeed, with increasing recognition of ulcerative colitis as a progressive disease rather than a disorder with periodic flares, 22 the threshold for introducing biologic drugs is steadily being lowered. 23 Few head to head comparisons of different anti-TNFs exist in this situation, although experience suggests that infliximab is preferable for treating active disease.…”

Section: Starting Anti-tnf Treatmentmentioning

confidence: 99%

Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease

Cohen

Sachar

2017

BMJ

115

View full text Add to dashboard Cite

The treatment of inflammatory bowel disease (IBD)-ulcerative colitis (UC) and Crohn's disease (CD)-has evolved beyond surgery with the introduction of biologic agents, primarily antibodies against mediators of inflammation and cell attraction. Anti-tumor necrosis factor (TNF) agents have been the first line treatment for moderate to severe ulcerative colitis and Crohn's disease for more than 15 years. During that time much has been learnt about how best to use these agents. This review will assess the evidence on how to optimize the use of anti-TNF agents; when and how to start treatment; how to monitor treatment and when to de-escalate it; and the potential adverse effects of these drugs. New and emerging treatments such as anti-attractants, anti-interleukins, and Janus kinase (JAK) inhibitors will also be discussed.

show abstract

“…49 A recent meta-analysis of RCTs, however, demonstrated that although infliximab and adalimumab were both associated with a reduction in hospitalizations, only infliximab was associated with a reduction in colectomy rates. 49, 50 Data regarding the long-term impact of vedolizumab on hospitalization and colectomy in UC is lacking.…”

Section: Tnf-antagonists and Vedolizumab: Comparative Effectiveness Omentioning

confidence: 99%

How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease

Dulai

Singh

Casteele

et al. 2016

Inflammatory Bowel Diseases

Self Cite

View full text Add to dashboard Cite

Several biologic agents have been added to our armamentarium of treatment options for moderate to severely active IBD, and this number is expected to only increase in the near future. With our growing understanding of disease mechanisms and pharmacokinetics, we are now able to target several mechanisms of action to achieve key end points (steroid free remission, mucosal healing) associated with improved long-term disease related outcomes. In this context, concerns arise regarding the optimal positioning of currently available biologics and key biologics in development. In this review, we will discuss the currently available evidence for comparative effectiveness of biologic agents approved for use in moderate to severely active IBD, with a focus on practical considerations to be made when utilizing these agents in practice. We will further review novel biologic agents and small molecule inhibitors in development and discuss future opportunities through which providers may personalize treatment decisions to achieve optimal treatment outcomes.

show abstract

Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials

Cited by 37 publications

References 32 publications

Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis

Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis

Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease

How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease

Contact Info

Product

Resources

About